{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-21-000039","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.659434+00:00","generated_at":"2026-06-29T13:37:15.540927+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Werewolf Therapeutics reports Q2 2021 net loss $10.9M; cash of $183.2M after IPO","bullets":["Completed May 2021 IPO: 7.5M shares at $16.00, net proceeds $109.2M.","Cash and cash equivalents $183.2M at June 30, 2021, up from $92.6M at Dec 31, 2020.","Q2 2021 net loss $10.9M vs $2.3M Q2 2020; R&D expenses $7.3M vs $3.8M.","Appointed Chulani Karunatilake as CTO and Mike Sherman to Board of Directors.","Existing cash expected to fund operations through at least Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-21-000039","json":"https://secwatch.observer/filing/0001785530-21-000039.json","markdown":"https://secwatch.observer/filing/0001785530-21-000039.md","text":"https://secwatch.observer/filing/0001785530-21-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553021000039/0001785530-21-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553021000039/howl-20210812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T13:37:15.540927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}